Share Price and Basic Stock Data
Last Updated: February 2, 2026, 4:53 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Arunjyoti Bio Ventures Ltd operates in the trading and distribution sector, with its share price currently at ₹7.03 and a market capitalization of ₹131 Cr. The company has shown a gradual increase in revenue, with reported sales rising from ₹0.00 in September 2022 to ₹3.14 Cr in September 2023, and further to ₹5.79 Cr by December 2023. The annual sales figures reflect a significant recovery, with ₹20.43 Cr reported for March 2024 and projected to reach ₹27.88 Cr by March 2025. This trend indicates a robust upward trajectory in revenue generation, aligning with strategic initiatives to enhance operational capabilities. However, the company recorded net profits of -₹2.29 Cr, underscoring challenges in converting revenue into profit, a common issue in the trading sector where margins can be thin.
Profitability and Efficiency Metrics
Profitability metrics for Arunjyoti Bio Ventures Ltd reveal variability, with operating profit margins fluctuating significantly. The operating profit margin (OPM) stood at 4.87% as of the most recent reporting period, down from a peak of 35.05% in June 2024, indicating volatility in expense management relative to sales growth. The return on equity (ROE) was reported at 10.7%, while the return on capital employed (ROCE) was significantly lower at 4.03%. The interest coverage ratio (ICR) of 2.04x suggests that the company is managing its interest obligations adequately, but the net profit margin dipped to -6.53%, indicating a need for improved cost control and operational efficiency. The cash conversion cycle (CCC) of 234.82 days raises concerns about liquidity and operational efficiency compared to industry averages, which typically range lower.
Balance Sheet Strength and Financial Ratios
As of the latest reporting, Arunjyoti Bio Ventures Ltd’s balance sheet reflects a reserve of ₹15.24 Cr against borrowings of ₹24.13 Cr, indicating a leverage ratio that may raise concerns among investors. The company reported a book value per share of ₹1.74, which is significantly lower than the market price, resulting in a price-to-book value (P/BV) ratio of 7.71x. The current ratio stood at 2.80, suggesting adequate short-term liquidity, while the quick ratio was slightly lower at 2.30, indicating the company’s ability to cover immediate liabilities without relying on inventory sales. The total debt to equity ratio of 0.79x reflects a relatively high level of debt compared to equity, which could pose risks if the company does not manage its operational efficiency effectively. The enterprise value (EV) of ₹274.59 Cr further emphasizes the company’s valuation concerns relative to its operational revenue.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Arunjyoti Bio Ventures Ltd indicates a mixed landscape of ownership. As of March 2025, promoters held 47.64% of the company, down from a peak of 61.79% in June 2024, suggesting a potential dilution of control or exit of some promoter interests. Public shareholders accounted for 52.36%, showing a diverse ownership base with 5,321 total shareholders. The increase in the number of shareholders from 452 in December 2022 to over 5,300 by March 2025 indicates growing public interest. Despite this, the decline in promoter holding can raise questions regarding long-term commitment and confidence in the company’s future. The lack of foreign institutional investment (FIIs) and domestic institutional investment (DIIs) points to a cautious stance from larger investors, which could impact future capital raising efforts.
Outlook, Risks, and Final Insight
The outlook for Arunjyoti Bio Ventures Ltd hinges on its ability to stabilize profitability while managing operational costs effectively. The company faces risks, including high dependency on revenue growth to cover losses, as reflected in the negative net profit margins and the substantial cash conversion cycle. Moreover, the significant decline in promoter shareholding could indicate underlying concerns regarding the company’s strategic direction. Addressing these issues through cost management and enhancing operational efficiencies will be crucial. Conversely, the growing public interest in the company and improving sales figures present opportunities for future growth. If operational efficiencies are realized and profitability is restored, Arunjyoti Bio Ventures may position itself for a stronger market presence in the trading sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Millennium Online Solutions (India) Ltd | 7.50 Cr. | 1.50 | 2.88/1.40 | 0.81 | 0.00 % | 4.61 % | 5.54 % | 1.00 | |
| Minal Industries Ltd | 54.7 Cr. | 2.85 | 5.59/2.50 | 36.5 | 2.78 | 0.00 % | 5.97 % | 2.83 % | 2.00 |
| Mitshi India Ltd | 11.1 Cr. | 12.6 | 17.8/11.7 | 3.09 | 0.00 % | 0.36 % | 0.37 % | 10.0 | |
| Modella Woollens Ltd | 5.49 Cr. | 60.4 | 74.8/52.5 | 4.95 | 0.00 % | % | % | 10.0 | |
| MRC Agrotech Ltd | 147 Cr. | 47.0 | 54.5/10.2 | 164 | 15.1 | 0.00 % | 5.89 % | 4.46 % | 10.0 |
| Industry Average | 8,559.53 Cr | 150.15 | 86.03 | 120.60 | 0.43% | 15.22% | 8.81% | 7.62 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0.00 | 0.48 | 1.26 | 2.80 | 3.14 | 5.79 | 8.70 | 10.10 | 6.35 | 6.15 | 5.28 | 8.71 | 5.34 |
| Expenses | 0.02 | 0.44 | 1.10 | 2.74 | 3.49 | 3.97 | 7.46 | 6.56 | 5.57 | 5.81 | 4.94 | 5.11 | 5.08 |
| Operating Profit | -0.02 | 0.04 | 0.16 | 0.06 | -0.35 | 1.82 | 1.24 | 3.54 | 0.78 | 0.34 | 0.34 | 3.60 | 0.26 |
| OPM % | 8.33% | 12.70% | 2.14% | -11.15% | 31.43% | 14.25% | 35.05% | 12.28% | 5.53% | 6.44% | 41.33% | 4.87% | |
| Other Income | 0.10 | -0.00 | -0.00 | 0.01 | 0.07 | -0.00 | -0.04 | 0.10 | 0.11 | 0.06 | 0.01 | 0.01 | 0.01 |
| Interest | -0.00 | -0.00 | -0.01 | 0.01 | 0.57 | 0.71 | 0.80 | 0.67 | 0.67 | 0.65 | 0.59 | 0.62 | 0.51 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | 0.54 | 0.67 | 0.81 | 0.72 | 0.74 | 0.78 | 0.80 | 0.82 | 0.83 |
| Profit before tax | 0.08 | 0.04 | 0.17 | 0.06 | -1.39 | 0.44 | -0.41 | 2.25 | -0.52 | -1.03 | -1.04 | 2.17 | -1.07 |
| Tax % | 12.50% | 25.00% | -0.00% | 16.67% | -0.72% | 163.64% | -407.32% | 24.89% | -59.62% | 7.77% | 91.35% | 5.53% | 14.02% |
| Net Profit | 0.07 | 0.03 | 0.17 | 0.04 | -1.37 | -0.28 | 1.26 | 1.69 | -0.22 | -1.12 | -1.99 | 2.05 | -1.23 |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.00 | -0.07 | -0.02 | 0.07 | 0.09 | -0.01 | -0.06 | -0.11 | 0.11 | -0.07 |
Last Updated: February 3, 2026, 3:46 am
Below is a detailed analysis of the quarterly data for Arunjyoti Bio Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 5.34 Cr.. The value appears to be declining and may need further review. It has decreased from 8.71 Cr. (Jun 2025) to 5.34 Cr., marking a decrease of 3.37 Cr..
- For Expenses, as of Sep 2025, the value is 5.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.11 Cr. (Jun 2025) to 5.08 Cr., marking a decrease of 0.03 Cr..
- For Operating Profit, as of Sep 2025, the value is 0.26 Cr.. The value appears to be declining and may need further review. It has decreased from 3.60 Cr. (Jun 2025) to 0.26 Cr., marking a decrease of 3.34 Cr..
- For OPM %, as of Sep 2025, the value is 4.87%. The value appears to be declining and may need further review. It has decreased from 41.33% (Jun 2025) to 4.87%, marking a decrease of 36.46%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.01 Cr..
- For Interest, as of Sep 2025, the value is 0.51 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.62 Cr. (Jun 2025) to 0.51 Cr., marking a decrease of 0.11 Cr..
- For Depreciation, as of Sep 2025, the value is 0.83 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Jun 2025) to 0.83 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Sep 2025, the value is -1.07 Cr.. The value appears to be declining and may need further review. It has decreased from 2.17 Cr. (Jun 2025) to -1.07 Cr., marking a decrease of 3.24 Cr..
- For Tax %, as of Sep 2025, the value is 14.02%. The value appears to be increasing, which may not be favorable. It has increased from 5.53% (Jun 2025) to 14.02%, marking an increase of 8.49%.
- For Net Profit, as of Sep 2025, the value is -1.23 Cr.. The value appears to be declining and may need further review. It has decreased from 2.05 Cr. (Jun 2025) to -1.23 Cr., marking a decrease of 3.28 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.07. The value appears to be declining and may need further review. It has decreased from 0.11 (Jun 2025) to -0.07, marking a decrease of 0.18.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.08 | 0.00 | 0.21 | 39.27 | 0.05 | 3.72 | 6.74 | 5.51 | 2.94 | 1.74 | 20.43 | 27.88 | 25.48 |
| Expenses | 0.07 | 0.02 | 0.27 | 39.03 | 0.28 | 3.68 | 6.61 | 5.41 | 3.14 | 1.57 | 17.65 | 22.86 | 20.94 |
| Operating Profit | 0.01 | -0.02 | -0.06 | 0.24 | -0.23 | 0.04 | 0.13 | 0.10 | -0.20 | 0.17 | 2.78 | 5.02 | 4.54 |
| OPM % | 12.50% | -28.57% | 0.61% | -460.00% | 1.08% | 1.93% | 1.81% | -6.80% | 9.77% | 13.61% | 18.01% | 17.82% | |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.00 | 0.04 | 0.28 | 0.09 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 2.11 | 2.59 | 2.37 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 3.05 | 3.23 |
| Profit before tax | 0.00 | -0.03 | -0.07 | 0.24 | -0.24 | 0.04 | 0.13 | 0.09 | 0.08 | 0.16 | -1.30 | -0.34 | -0.97 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 0.00% | 23.08% | 22.22% | 25.00% | 25.00% | -73.08% | 435.29% | ||
| Net Profit | 0.00 | -0.04 | -0.07 | 0.20 | -0.25 | 0.04 | 0.11 | 0.07 | 0.06 | 0.12 | -0.35 | -1.82 | -2.29 |
| EPS in Rs | 0.00 | -0.00 | -0.00 | 0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | -0.02 | -0.10 | -0.13 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -75.00% | 385.71% | -225.00% | 116.00% | 175.00% | -36.36% | -14.29% | 100.00% | -391.67% | -420.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 460.71% | -610.71% | 341.00% | 59.00% | -211.36% | 22.08% | 114.29% | -491.67% | -28.33% |
Arunjyoti Bio Ventures Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 112% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -189% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 117% |
| 3 Years: | 115% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -8% |
| 3 Years: | -10% |
| Last Year: | -11% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:24 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 2.07 | 18.64 | 18.64 |
| Reserves | -0.19 | -0.23 | -0.30 | -0.10 | -0.34 | -0.30 | -0.19 | -0.13 | -0.07 | 0.04 | -0.30 | 13.74 | 15.24 |
| Borrowings | 0.00 | 0.00 | 0.04 | 0.19 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 32.27 | 51.40 | 26.21 | 24.13 |
| Other Liabilities | 0.11 | 0.13 | 0.36 | 17.70 | 8.36 | 3.71 | 4.02 | 2.77 | 0.09 | 1.53 | 0.82 | 1.03 | 1.08 |
| Total Liabilities | 1.99 | 1.97 | 2.17 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 35.91 | 53.99 | 59.62 | 59.09 |
| Fixed Assets | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.50 | 43.33 | 46.92 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.19 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 1.96 | 1.95 | 2.16 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 16.72 | 13.49 | 16.29 | 12.17 |
| Total Assets | 1.99 | 1.97 | 2.17 | 19.86 | 10.28 | 5.48 | 5.90 | 4.71 | 2.09 | 35.91 | 53.99 | 59.62 | 59.09 |
Below is a detailed analysis of the balance sheet data for Arunjyoti Bio Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.64 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.64 Cr..
- For Reserves, as of Sep 2025, the value is 15.24 Cr.. The value appears strong and on an upward trend. It has increased from 13.74 Cr. (Mar 2025) to 15.24 Cr., marking an increase of 1.50 Cr..
- For Borrowings, as of Sep 2025, the value is 24.13 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 26.21 Cr. (Mar 2025) to 24.13 Cr., marking a decrease of 2.08 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1.08 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.03 Cr. (Mar 2025) to 1.08 Cr., marking an increase of 0.05 Cr..
- For Total Liabilities, as of Sep 2025, the value is 59.09 Cr.. The value appears to be improving (decreasing). It has decreased from 59.62 Cr. (Mar 2025) to 59.09 Cr., marking a decrease of 0.53 Cr..
- For Fixed Assets, as of Sep 2025, the value is 46.92 Cr.. The value appears strong and on an upward trend. It has increased from 43.33 Cr. (Mar 2025) to 46.92 Cr., marking an increase of 3.59 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 12.17 Cr.. The value appears to be declining and may need further review. It has decreased from 16.29 Cr. (Mar 2025) to 12.17 Cr., marking a decrease of 4.12 Cr..
- For Total Assets, as of Sep 2025, the value is 59.09 Cr.. The value appears to be declining and may need further review. It has decreased from 59.62 Cr. (Mar 2025) to 59.09 Cr., marking a decrease of 0.53 Cr..
However, the Borrowings (24.13 Cr.) are higher than the Reserves (15.24 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.01 | -0.02 | -0.10 | 0.05 | -0.42 | 0.04 | 0.13 | 0.10 | -0.20 | -32.10 | -48.62 | -21.19 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 821.25 | 677.86 | 159.68 | 32,923.00 | 231.56 | 144.59 | 121.89 | 67.04 | 163.62 | 48.77 | 51.97 | |
| Inventory Days | 0.00 | 61.61 | 1.80 | 2.34 | 0.00 | 214.13 | 125.52 | 182.85 | ||||
| Days Payable | 245.27 | 130.66 | 102.39 | 0.00 | 16.71 | 0.00 | ||||||
| Cash Conversion Cycle | 821.25 | 677.86 | 159.68 | 32,923.00 | 47.90 | 15.73 | 21.84 | 67.04 | 377.75 | 157.59 | 234.82 | |
| Working Capital Days | 319.38 | 52.14 | 2.14 | -22,703.00 | -6.87 | -40.07 | -23.85 | 122.91 | 834.89 | 109.88 | 116.78 | |
| ROCE % | 0.00% | -1.61% | -3.84% | 12.09% | -11.27% | 2.17% | 7.12% | 5.24% | 4.06% | 0.93% | 1.85% | 4.03% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.10 | -1.68 | 0.56 | 0.27 | 0.33 |
| Diluted EPS (Rs.) | -0.10 | -1.68 | 0.56 | 0.27 | 0.33 |
| Cash EPS (Rs.) | 0.06 | 8.04 | 0.56 | 0.27 | 0.32 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.74 | 8.53 | 10.22 | 9.66 | 9.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.74 | 8.53 | 10.22 | 9.66 | 9.39 |
| Revenue From Operations / Share (Rs.) | 1.50 | 98.66 | 8.38 | 14.35 | 26.62 |
| PBDIT / Share (Rs.) | 0.28 | 13.55 | 0.78 | 0.37 | 0.45 |
| PBIT / Share (Rs.) | 0.12 | 3.83 | 0.78 | 0.37 | 0.45 |
| PBT / Share (Rs.) | -0.01 | -6.27 | 0.76 | 0.36 | 0.44 |
| Net Profit / Share (Rs.) | -0.09 | -1.68 | 0.56 | 0.27 | 0.32 |
| PBDIT Margin (%) | 18.98 | 13.73 | 9.38 | 2.59 | 1.70 |
| PBIT Margin (%) | 8.06 | 3.88 | 9.38 | 2.59 | 1.70 |
| PBT Margin (%) | -1.22 | -6.35 | 9.09 | 2.55 | 1.67 |
| Net Profit Margin (%) | -6.53 | -1.70 | 6.73 | 1.89 | 1.23 |
| Return on Networth / Equity (%) | -5.62 | -19.74 | 5.52 | 2.81 | 3.50 |
| Return on Capital Employeed (%) | 4.13 | 1.62 | 0.47 | 3.84 | 4.82 |
| Return On Assets (%) | -3.05 | -0.64 | 0.32 | 2.68 | 1.45 |
| Long Term Debt / Equity (X) | 0.64 | 26.38 | 15.26 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.79 | 28.73 | 15.26 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.49 | 0.45 | 0.09 | 0.87 | 1.04 |
| Current Ratio (X) | 2.80 | 2.24 | 3.64 | 11.67 | 1.16 |
| Quick Ratio (X) | 2.30 | 1.66 | 3.06 | 11.67 | 1.15 |
| Inventory Turnover Ratio (X) | 10.04 | 0.00 | 0.00 | 221.57 | 0.00 |
| Interest Coverage Ratio (X) | 2.04 | 1.34 | 32.67 | 78.09 | 59.74 |
| Interest Coverage Ratio (Post Tax) (X) | 0.29 | 0.83 | 24.43 | 58.04 | 44.47 |
| Enterprise Value (Cr.) | 274.59 | 62.47 | 69.78 | 5.17 | 0.61 |
| EV / Net Operating Revenue (X) | 9.85 | 3.06 | 40.21 | 1.74 | 0.11 |
| EV / EBITDA (X) | 51.87 | 22.26 | 428.45 | 67.13 | 6.52 |
| MarketCap / Net Operating Revenue (X) | 8.95 | 0.57 | 21.63 | 1.74 | 0.25 |
| Price / BV (X) | 7.71 | 6.68 | 17.74 | 2.59 | 0.73 |
| Price / Net Operating Revenue (X) | 8.95 | 0.57 | 21.63 | 1.74 | 0.25 |
| EarningsYield | -0.01 | -0.02 | 0.00 | 0.01 | 0.04 |
After reviewing the key financial ratios for Arunjyoti Bio Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 1.00, marking a decrease of 9.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has increased from -1.68 (Mar 24) to -0.10, marking an increase of 1.58.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has increased from -1.68 (Mar 24) to -0.10, marking an increase of 1.58.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 3. It has decreased from 8.04 (Mar 24) to 0.06, marking a decrease of 7.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.74. It has decreased from 8.53 (Mar 24) to 1.74, marking a decrease of 6.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.74. It has decreased from 8.53 (Mar 24) to 1.74, marking a decrease of 6.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.50. It has decreased from 98.66 (Mar 24) to 1.50, marking a decrease of 97.16.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 2. It has decreased from 13.55 (Mar 24) to 0.28, marking a decrease of 13.27.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.12. This value is within the healthy range. It has decreased from 3.83 (Mar 24) to 0.12, marking a decrease of 3.71.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.01. This value is below the healthy minimum of 0. It has increased from -6.27 (Mar 24) to -0.01, marking an increase of 6.26.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 2. It has increased from -1.68 (Mar 24) to -0.09, marking an increase of 1.59.
- For PBDIT Margin (%), as of Mar 25, the value is 18.98. This value is within the healthy range. It has increased from 13.73 (Mar 24) to 18.98, marking an increase of 5.25.
- For PBIT Margin (%), as of Mar 25, the value is 8.06. This value is below the healthy minimum of 10. It has increased from 3.88 (Mar 24) to 8.06, marking an increase of 4.18.
- For PBT Margin (%), as of Mar 25, the value is -1.22. This value is below the healthy minimum of 10. It has increased from -6.35 (Mar 24) to -1.22, marking an increase of 5.13.
- For Net Profit Margin (%), as of Mar 25, the value is -6.53. This value is below the healthy minimum of 5. It has decreased from -1.70 (Mar 24) to -6.53, marking a decrease of 4.83.
- For Return on Networth / Equity (%), as of Mar 25, the value is -5.62. This value is below the healthy minimum of 15. It has increased from -19.74 (Mar 24) to -5.62, marking an increase of 14.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.13. This value is below the healthy minimum of 10. It has increased from 1.62 (Mar 24) to 4.13, marking an increase of 2.51.
- For Return On Assets (%), as of Mar 25, the value is -3.05. This value is below the healthy minimum of 5. It has decreased from -0.64 (Mar 24) to -3.05, marking a decrease of 2.41.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.64. This value is within the healthy range. It has decreased from 26.38 (Mar 24) to 0.64, marking a decrease of 25.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.79. This value is within the healthy range. It has decreased from 28.73 (Mar 24) to 0.79, marking a decrease of 27.94.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.49. It has increased from 0.45 (Mar 24) to 0.49, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 2.80. This value is within the healthy range. It has increased from 2.24 (Mar 24) to 2.80, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 2.30. This value exceeds the healthy maximum of 2. It has increased from 1.66 (Mar 24) to 2.30, marking an increase of 0.64.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 10.04. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 10.04, marking an increase of 10.04.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.04. This value is below the healthy minimum of 3. It has increased from 1.34 (Mar 24) to 2.04, marking an increase of 0.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 3. It has decreased from 0.83 (Mar 24) to 0.29, marking a decrease of 0.54.
- For Enterprise Value (Cr.), as of Mar 25, the value is 274.59. It has increased from 62.47 (Mar 24) to 274.59, marking an increase of 212.12.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 9.85. This value exceeds the healthy maximum of 3. It has increased from 3.06 (Mar 24) to 9.85, marking an increase of 6.79.
- For EV / EBITDA (X), as of Mar 25, the value is 51.87. This value exceeds the healthy maximum of 15. It has increased from 22.26 (Mar 24) to 51.87, marking an increase of 29.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.95. This value exceeds the healthy maximum of 3. It has increased from 0.57 (Mar 24) to 8.95, marking an increase of 8.38.
- For Price / BV (X), as of Mar 25, the value is 7.71. This value exceeds the healthy maximum of 3. It has increased from 6.68 (Mar 24) to 7.71, marking an increase of 1.03.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.95. This value exceeds the healthy maximum of 3. It has increased from 0.57 (Mar 24) to 8.95, marking an increase of 8.38.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to -0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Arunjyoti Bio Ventures Ltd:
- Net Profit Margin: -6.53%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.13% (Industry Average ROCE: 15.22%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -5.62% (Industry Average ROE: 8.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.29
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 86.03)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.79
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -6.53%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Trading & Distributors | Door No.1-98/1/JSIC/6F/604-B, 6th Floor, Madha Telangana 500081 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pabbathi Badari Narayana Murthy | Whole Time Director |
| Mr. Dathivik Pabbathi | Whole Time Director |
| Mr. Vishal Nadimpalli | WholeTime Director & CFO |
| Mr. Vijaya Rama Lakshmana Murthy | Independent Director |
| Mrs. Dhanalakshmi Guntaka | Independent Director |
| Mr. Srikar Ranga | Independent Director |
FAQ
What is the intrinsic value of Arunjyoti Bio Ventures Ltd?
Arunjyoti Bio Ventures Ltd's intrinsic value (as of 05 February 2026) is ₹2.32 which is 67.60% lower the current market price of ₹7.16, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹133 Cr. market cap, FY2025-2026 high/low of ₹16.7/5.05, reserves of ₹15.24 Cr, and liabilities of ₹59.09 Cr.
What is the Market Cap of Arunjyoti Bio Ventures Ltd?
The Market Cap of Arunjyoti Bio Ventures Ltd is 133 Cr..
What is the current Stock Price of Arunjyoti Bio Ventures Ltd as on 05 February 2026?
The current stock price of Arunjyoti Bio Ventures Ltd as on 05 February 2026 is ₹7.16.
What is the High / Low of Arunjyoti Bio Ventures Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Arunjyoti Bio Ventures Ltd stocks is ₹16.7/5.05.
What is the Stock P/E of Arunjyoti Bio Ventures Ltd?
The Stock P/E of Arunjyoti Bio Ventures Ltd is .
What is the Book Value of Arunjyoti Bio Ventures Ltd?
The Book Value of Arunjyoti Bio Ventures Ltd is 1.82.
What is the Dividend Yield of Arunjyoti Bio Ventures Ltd?
The Dividend Yield of Arunjyoti Bio Ventures Ltd is 0.00 %.
What is the ROCE of Arunjyoti Bio Ventures Ltd?
The ROCE of Arunjyoti Bio Ventures Ltd is 4.03 %.
What is the ROE of Arunjyoti Bio Ventures Ltd?
The ROE of Arunjyoti Bio Ventures Ltd is 10.7 %.
What is the Face Value of Arunjyoti Bio Ventures Ltd?
The Face Value of Arunjyoti Bio Ventures Ltd is 1.00.